Phase 3 Trial of ION-1 Will Continue
Gilead To Continue Phase 3 Trial Of Hepatitis C Compound Without Change
By RTT News, March 26, 2013
RTTNews.com) – Biopharmaceutical company Gilead Sciences Inc. ( GILD ) Tuesday said the phase 3 trial ION-1, evaluating once-daily fixed-dose combination of the nucleotide sofosbuvir and the NS5A inhibitor ledipasvir with and without ribavirin for 12 or 24 weeks among treatment-naÃ¯ve genotype 1 patients with hepatitis C virus infection should continue without any modification.
Continue reading this entire article:
Can Miravirsen Stop HCV with Little Side Effects?
Dental Practice Possibly Exposes 7,000 Patients to Hepatitis and HIV